eMedicine Specialties > Emergency Medicine > Infectious Diseases

Brain Abscess: Treatment & Medication

Author: Lisa Elizabeth Thomas, MD, Staff Physician, Harvard Affiliated Emergency Medicine Residency, Brigham and Women's Hospital and Massachusetts General Hospital
Coauthor(s): Joshua N Goldstein, MD, PhD, FAAEM, Assistant Professor of Surgery (Emergency Medicine), Harvard Medical School; Attending Physician, Department of Emergency Medicine, Massachusetts General Hospital
Contributor Information and Disclosures

Updated: Sep 25, 2008

Treatment

Prehospital Care

Rapid transport is the key component of prehospital care for suspected intracranial abscess.

Emergency Department Care

  • The initial evaluation is dictated by the severity of the patient's condition.
  • Emergent intubation using a cerebroprotective rapid sequence induction regimen is often necessary in patients with obtundation, inability to protect the airway, and suspected herniation.
  • Stable patients whose presentation suggests the diagnosis should undergo rapid neuroimaging after initial evaluation.2 ,3 ,7 Close monitoring of neurologic status is essential and having at least one nurse or advanced provider in attendance while the patient is undergoing imaging is probably advisable.
  • Antibiotics should be administered as early as possible in the patient's course in the ED. These may be given prior to imaging in cases where the diagnosis is very strongly suspected.11
  • Seizures should be treated aggressively to decrease the risk of sustained increases in intracranial pressure. Prophylactic anticonvulsants are often used given the relatively high frequency of seizures in this population.3

Consultations

  • Once the diagnosis is clear, immediate neurosurgical consultation is mandatory.2,3
  • Infectious disease consultation may be necessary to optimize antibiotic therapy, especially in immunocompromised hosts.2,4
  • Neurology consultation is helpful in guiding both immediate and long-term management.

Medication

Selection of appropriate antimicrobials with adequate CNS penetration and coverage of typical anaerobic and aerobic organisms is critical in controlling infection and preventing complications.

In the early phase of abscess formation, cerebritis, patients may respond to antibiotic therapy alone.7,5

However, in almost all cases, definitive treatment of brain abscess requires surgical drainage.2,3

Since seizures are a frequent complication of brain abscess, anticonvulsants for seizure prophylaxis are often recommended at the initial time of diagnosis and for a prolonged period of time, often greater than 1 year.3,7

Antibiotics

In the ED, empirical regimens of antibiotic therapy are the first-line pharmacologic treatment of brain abscess based on presumed source:3  

  • Direct extension from sinuses, teeth, middle ear - Penicillin G + metronidazole + third-generation cephalosporin
  • Hematogenous spread or penetrating trauma - Nafcillin + metronidazole + third-generation cephalosporin
  • Postoperative - Vancomycin (concern for MRSA) + ceftazidime or cefepime (concern for Pseudomonas)
  • No predisposing factor - Metronidazole + vancomycin + third-generation cephalosporin

Imipenem or meropenem can also be used for broad-spectrum coverage when other drug toxicities are unacceptable, but imipenem has been associated with seizures in patients with brain abscess.4

Additional targeted therapy may also be initiated in suspected fungal or protozoan infections, especially in immunocompromised patients.2


Ceftriaxone (Rocephin)

Third-generation cephalosporin with broad-spectrum, gram-negative activity; lower efficacy against gram-positive organisms; higher efficacy against resistant organisms. Bactericidal activity results from inhibiting cell wall synthesis by binding to one or more penicillin-binding proteins. Exerts antimicrobial effect by interfering with synthesis of peptidoglycan, a major structural component of bacterial cell wall. Bacteria eventually lyse due to the ongoing activity of cell wall autolytic enzymes while cell wall assembly is arrested.
Highly stable in presence of beta-lactamases, both penicillinase and cephalosporinase, of gram-negative and gram-positive bacteria.

Adult

2 g IV q12-24h, max 4 g/d

Pediatric

100 mg/kg/d IV divided q12h

Probenecid may increase ceftriaxone levels; coadministration with ethacrynic acid, furosemide, and aminoglycosides may increase nephrotoxicity

Documented hypersensitivity; hyperbilirubinemic neonates, particularly those who are premature

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy; caution in breastfeeding women; may displace bilirubin from albumin binding sites increasing the risk of kernicterus; caution with gallbladder, biliary tract, liver, or pancreatic disease; caution in patients with history of colitis or penicillin hypersensitivity


Cefepime (Maxipime)

Fourth-generation cephalosporin. Gram-negative coverage comparable to ceftazidime but has better gram-positive coverage (comparable to ceftriaxone). Covers Pseudomonas.

Adult

2 g IV q8-12h

Pediatric

Neonates: 30 mg/kg IV q12h
>2 months: 50 mg/kg IV q8h (max 2 g/dose)

Probenecid may increase effects of cefepime; aminoglycosides increase the nephrotoxic potential of cefepime

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Dosage adjustments (adult adjustments)
CrCl (mL/min) 80-50: 0.5-2 g q12-24h
CrCl 50-10: 0.5-2 g/d
CrCl <10: 0.25-0.5 g/d
HD: As for CrCl <10, with an extra 0.25 g after HD
During peritoneal dialysis: 1-2 g q48h
High doses may cause CNS toxicity; prolonged use of cefepime may predispose patients to superinfection


Imipenem and cilastatin (Primaxin)

For treatment of multiple organism infections in which other agents do not have wide spectrum coverage or are contraindicated due to potential for toxicity.

Adult

500-750 mg IV q6h; in healthy young adults with excellent renal function, doses of 1 g q6h may be necessary (max dose: 4 g/d)

Pediatric

Infants >3 months and children <12 years: 15-25 mg/kg/dose IV q6h
Fully susceptible organisms: Not to exceed 2 g/d
Infections with moderately susceptible organisms: Not to exceed 4 g/d
>12 years: Administer as in adults

Coadministration with cyclosporine may increase CNS side effects of both agents; coadministration with ganciclovir may result in generalized seizures

Documented hypersensitivity; known hypersensitivity to amide local anesthetics; children with CNS infections (increased seizure risk); children <30 kg with renal impairment (lack of data)

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Adjust dose in renal insufficiency (adult adjustments)
CrCl (mL/min) 80-50: 0.5 g q6-8h
CrCl 50-10: 0.5 g q8-12h
Hemodialysis (HD): 0.25-0.5 g after HD, then q12h
Adjust dose in renal insufficiency; avoid use in children <12 y with CNS infections
Caution with history of seizures, hypersensitivity to penicillins, cephalosporins, or other beta-lactam antibiotics


Meropenem (Merrem IV)

Bactericidal broad-spectrum carbapenem antibiotic that inhibits cell-wall synthesis. Effective against most gram-positive and gram-negative bacteria. Has slightly increased activity against gram-negatives and slightly decreased activity against staphylococci and streptococci compared with imipenem.

Adult

1-2 g IV q8h

Pediatric

<3 months: Not established
>3 months: 40 mg/kg IV q8h (max dose 2 g/dose)

Probenecid may inhibit renal excretion of meropenem, increasing meropenem levels

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Dosage adjustments (adult adjustments)
CrCl (mL/min) 10-50: 0.5-1 g q12h
CrCl <10: 0.5 g/d
HD: As for CrCl <10, with an extra 0.5 g after HD
Pseudomembranous colitis and thrombocytopenia may occur, requiring immediate discontinuation of medication


Penicillin G (Pfizerpen)

May be used as first-line regimen for empiric treatment of brain abscess in ED. Provides coverage for anaerobes and streptococci. Penetrates well into abscess cavity.

Adult

6 million U IV q6h

Pediatric

<14 kg (30 lb): 600,000 U IV q6h
14-27 kg (30-60 lb): 900,000-1,200,000 U IV q6h
>27 kg (>60 lb): Administer as in adults

Probenecid can increase effects; tetracyclines can decrease effects

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Caution in impaired renal function


Metronidazole (Flagyl)

First line. Imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. Has proved especially effective in otogenic brain abscesses.

Adult

500-750 mg IV q6h

Pediatric

30 mg/kg/d IV

May increase toxicity of anticoagulants, lithium, and phenytoin; cimetidine may increase toxicity; disulfiram reaction may occur with orally ingested ethanol

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Adjust dose in hepatic disease; monitor for seizures and development of peripheral neuropathy


Cefotaxime (Claforan)

First line. Covers streptococci, staphylococci, and Haemophilus and Enterobacter species. This third-generation cephalosporin has broad gram-negative spectrum, lower efficacy against gram-positive organisms, and higher efficacy against resistant organisms than earlier generation cephalosporins. Arrests bacteria cell wall synthesis and inhibits bacterial growth by binding to 1 or more penicillin-binding proteins.

Adult

2g IV q4-6h

Pediatric

Neonates: 50-200 mg/kg/d IV
Infants and children: 200 mg/kg/d IV divided into q6h-q8h

Probenecid may increase levels; coadministration with furosemide or aminoglycosides may increase nephrotoxicity

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Adjust dose in severe renal impairment; has been associated with severe colitis


Nafcillin (Unipen)

Treats infections caused by penicillinase-producing staphylococci. Used to initiate therapy when penicillin G-resistant staphylococcal infection suspected. Do not use for treatment of penicillin G-susceptible staphylococci. Use parenteral therapy initially in severe infections. Very severe infections may require very high doses. Change to oral therapy as condition improves. Because of occasional occurrence of thrombophlebitis associated with parenteral route (particularly in elderly persons) administer parenterally only for short term (24-48 h) and change to oral route if clinically possible.

Adult

2g IV q4h

Pediatric

Neonates:
1200-2000 g, <7 days: 50 mg/kg/d IV divided q12h
>2000 g and <7 days or 1200-2000g and >7 days: 75 mg/kg/d IV divided q8h
>2000 g, >7 days: 100-140 mg/kg/d IV divided q6h
Children: 200 mg/kg/d in divided doses q4-6h

Associated with warfarin resistance when administered concurrently; effects may decrease with bacteriostatic action of tetracycline derivatives

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

To optimize therapy, determine causative organisms and susceptibility; >10 d treatment needed to eliminate infection and prevent sequelae (eg, endocarditis, rheumatic fever); take cultures after treatment to confirm that infection is eradicated


Vancomycin (Vancocin)

Replaces nafcillin in both penicillin-allergic patients and those in whom MRSA is suspected as etiologic agent. Potent antibiotic directed against gram-positive organisms and active against enterococci. Also useful in treating septicemia and skin structure infections. Adjust dose as needed in patients with renal impairment. Check trough level after third dose (30 min prior to next dose) to avoid toxicity.

Adult

1 g IV q12h or loading dose of 15 mg/kg IV q8-12h
Dose for peaks 25-40 mcg/mL, troughs 5-10 mcg/mL

Pediatric

60 mg/kg/d IV in divided doses q6h

Erythema, histamine reactionlike flushing, and anaphylactic reactions may occur when administered with anesthetic agents; concurrent aminoglycosides may increase risk of nephrotoxicity above that with aminoglycoside monotherapy; concurrent nondepolarizing muscle relaxants may enhance effects of neuromuscular blockade

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in renal failure, neutropenia; adjust dose in patients with renal impairment; red man syndrome caused by too rapid IV infusion (ie, dose given over a few min) but rarely happens when dose given as 2-h infusion or by PO or IP route; red man syndrome not allergic reaction


Ceftazidime (Fortaz, Ceptaz)

Add to empiric regimens if pseudomonads are suspected. Third-generation cephalosporin that has broad gram-negative spectrum, lower efficacy against gram-positive organisms, and higher efficacy against resistant organisms than many agents. Arrests bacteria cell wall synthesis and inhibits bacterial growth by binding to 1 or more penicillin-binding proteins.

Adult

6 g/d IV

Pediatric

Not established

Nephrotoxicity may increase with aminoglycosides, furosemide, or ethacrynic acid; probenecid may increase levels

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Adjust dose in renal impairment

Corticosteroids

Use of steroids is controversial. The anti-inflammatory effects of steroid therapy can decrease cerebral edema, reducing intracranial pressure (ICP). These benefits are offset somewhat by the fact that steroid use decreases antibiotic penetration into the abscess and may slow encapsulation of the abscess site. Therefore, many authors recommend steroids only in cases of massive cerebral edema with impending herniation.3,11


Dexamethasone (Decadron, Dexasone)

Corticosteroid of choice for reducing ICP. Used in treatment of inflammatory diseases. May decrease inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability.

Adult

Loading dose: 10-12 mg IV
Maintenance dose: 4 mg IV q6h

Pediatric

Loading dose: 1-2 mg/kg/dose IV once
Maintenance dose: 1-1.5 mg/kg/d IV
Not to exceed 16 mg/d divided q4-6h for 5 d; taper dose for 5 d and discontinue

Effects decrease with coadministration of barbiturates, phenytoin, or rifampin; decreases effect of salicylates and vaccines used for immunization

Documented hypersensitivity, active bacterial or fungal infection

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Increases risk of multiple complications, including severe infections; monitor for adrenal insufficiency when tapering drug; abrupt discontinuation may cause adrenal crisis; possible complications include hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression, and infections

More on Brain Abscess

Overview: Brain Abscess
Differential Diagnoses & Workup: Brain Abscess
Treatment & Medication: Brain Abscess
Follow-up: Brain Abscess
References

References

  1. Alderson D, Strong AJ, Ingham HR, et al. Fifteen-year review of the mortality of brain abscess. Neurosurgery. Jan 1981;8(1):1-6. [Medline].

  2. Carpenter J, Stapleton S, Holliman R. Retrospective analysis of 49 cases of brain abscess and review of the literature. Eur J Clin Microbiol Infect Dis. Jan 2007;26(1):1-11. [Medline].

  3. Lu CH, Chang WN, Lui CC. Strategies for the management of bacterial brain abscess. J Clin Neurosci. Dec 2006;13(10):979-85. [Medline].

  4. Mathisen GE, Johnson JP. Brain abscess. Clin Infect Dis. Oct 1997;25(4):763-79; quiz 780-1. [Medline].

  5. Sáez-Llorens X. Brain abscess in children. Semin Pediatr Infect Dis. Apr 2003;14(2):108-14. [Medline].

  6. Bernardini GL. Diagnosis and management of brain abscess and subdural empyema. Curr Neurol Neurosci Rep. Nov 2004;4(6):448-56. [Medline].

  7. Mamelak AN, Mampalam TJ, Obana WG, et al. Improved management of multiple brain abscesses: a combined surgical and medical approach. Neurosurgery. 1995;36(1):76-85. [Medline].

  8. Yang KY, Chang WN, Ho JT, et al. Postneurosurgical nosocomial bacterial brain abscess in adults. Infection. Oct 2006;34(5):247-51. [Medline].

  9. Sennaroglu L, Sozeri B. Otogenic brain abscess: review of 41 cases. Otolaryngol Head Neck Surg. Dec 2000;123(6):751-5. [Medline].

  10. Gallitelli M, Lepore V, Pasculli G, et al. Brain abscess: a need to screen for pulmonary arteriovenous malformations. Neuroepidemiology. 2005;24(1-2):76-8. [Medline].

  11. Seydoux C, Francioli P. Bacterial brain abscesses: factors influencing mortality and sequelae. Clin Infect Dis. Sep 1992;15(3):394-401. [Medline].

  12. Vidal JE, Oliveira AC, Filho FB, et al. Tuberculous brain abscess in AIDS patients: report of three cases and literature review. Int J Infect Dis 9(4):201-7. 2005;9(4):201-7. [Medline].

  13. Kennedy KJ, Chung KH, Bowden FJ, et al. A cluster of nocardial brain abscesses. Surg Neurol. Jul 2007;68(1):43-9; discussion 49. [Medline].

  14. Wolf J, Curtis N. Brain abscess secondary to dental braces. Pediatr Infect Dis J. Jan 2008;27(1):84-5. [Medline].

  15. Gaïni S, Grand M, Michelsen J. Brain abscess after esophageal dilatation: case report. Infection. Feb 2008;36(1):71-3. [Medline].

  16. Roberts J, Bartlett AH, Giannoni CM, et al. Airway foreign bodies and brain abscesses: report of two cases and review of the literature. Int J Pediatr Otorhinolaryngol. Feb 2008;72(2):265-9. [Medline].

  17. Katragkou A, Dotis J, Kotsiou M, et al. Scedosporium apiospermum infection after near-drowning. Mycoses. Sep 2007;50(5):412-21. [Medline].

  18. Khouzam RN, El-Dokla AM, Menkes DL. Undiagnosed patent foramen ovale presenting as a cryptogenic brain abscess: case report and review of the literature. Heart Lung. Mar-Apr 2006;35(2):108-11. [Medline].

  19. Enany S, Higuchi W, Okubo T, et al. Brain abscess caused by Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus in Egypt, April 2007. Euro Surveill. Sep 27 2007;12(9):E070927.2. [Medline].

  20. Sifri CD, Park J, Helm GA, et al. Fatal brain abscess due to community-associated methicillin-resistant Staphylococcus aureus strain USA300. Clin Infect Dis. Nov 1 2007;45(9):e113-7. [Medline].

  21. Hakan T, Ceran N, Erdem I, et al. Bacterial brain abscesses: an evaluation of 96 cases. J Infect. May 2006;52(5):359-66. [Medline].

  22. Kao PT, Tseng HK, Liu CP, et al. Brain abscess: clinical analysis of 53 cases. J Microbiol Immunol Infect. Jun 2003;36(2):129-36. [Medline].

  23. Marshman LA, Connor S, Chandler CL. Persistent absence of ring-enhancement on CT with an encapsulated brain abscess. Br J Neurosurg. Aug 2004;18(4):377-82. [Medline].

  24. Kastrup O, Wanke I, Maschke M. Neuroimaging of infections. NeuroRx. Apr 2005;2(2):324-32. [Medline].

  25. Lai PH, Hsu SS, Ding SW, et al. Proton magnetic resonance spectroscopy and diffusion-weighted imaging in intracranial cystic mass lesions. Surg Neurol. 2007;68 Suppl 1:S25-36. [Medline].

  26. Kimberly HH, Shah S, Marill K, et al. Correlation of optic nerve sheath diameter with direct measurement of intracranial pressure. Acad Emerg Med. Feb 2008;15(2):201-4. [Medline].

  27. Hasbun R, Abrahams J, Jekel J, et al. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N Engl J Med. Dec 13 2001;345(24):1727-33. [Medline].

  28. Boviatsis EJ, Kouyialis AT, Stranjalis G, et al. CT-guided stereotactic aspiration of brain abscesses. Neurosurg Rev. Jul 2003;26(3):206-9. [Medline].

  29. Unal O, Sakarya ME, Kiymaz N, et al. Brain abscess drainage by use of MR fluoroscopic guidance. Am J Neuroradiol. 2005;26(4):839-42. [Medline].

  30. Kurschel S, Mohia A, Weigl V, et al. Hyperbaric oxygen therapy for the treatment of brain abscess in children. Childs Nerv Syst. 2005;May 5:[Medline].

  31. Kutlay M, Colak A, Yildiz S, et al. Stereotactic aspiration and antibiotic treatment combined with hyperbaric oxygen therapy in the management of bacterial brain abscesses. Neurosurgery. Dec 2005;57(6):1140-6; discussion 1140-6. [Medline].

  32. Lee TH, Chang WN, Su TM, et al. Clinical features and predictive factors of intraventricular rupture in patients who have bacterial brain abscesses. J Neurol Neurosurg Psychiatry. Mar 2007;78(3):303-9. [Medline].

  33. Xiao F, Tseng MY, Teng LJ, et al. Brain abscess: clinical experience and analysis of prognostic factors. Surg Neurol. May 2005;63(5):442-9; discussion 449-50. [Medline].

  34. Demir MK, Hakan T, Kilicoglu G, et al. Bacterial brain abscesses: prognostic value of an imaging severity index. Clin Radiol. Jun 2007;62(6):564-72. [Medline].

  35. Prasad KN, Mishra AM, Gupta D, et al. Analysis of microbial etiology and mortality in patients with brain abscess. J Infect. Oct 2006;53(4):221-7. [Medline].

Further Reading

Keywords

brain abscess, intracranial abscess, intracerebral abscess, cerebritis, cerebral abscess

Contributor Information and Disclosures

Author

Lisa Elizabeth Thomas, MD, Staff Physician, Harvard Affiliated Emergency Medicine Residency, Brigham and Women's Hospital and Massachusetts General Hospital
Lisa Elizabeth Thomas, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Coauthor(s)

Joshua N Goldstein, MD, PhD, FAAEM, Assistant Professor of Surgery (Emergency Medicine), Harvard Medical School; Attending Physician, Department of Emergency Medicine, Massachusetts General Hospital
Joshua N Goldstein, MD, PhD, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Stroke Association, and Society for Academic Emergency Medicine
Disclosure: CSL Behring Consulting fee Consulting; Genentech Consulting fee Consulting

Medical Editor

Edward Bessman, MD, Chairman, Department of Emergency Medicine, John Hopkins Bayview Medical Center; Assistant Professor, Department of Emergency Medicine, Johns Hopkins University
Edward Bessman, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Barry J Sheridan, DO, Chief, Department of Emergency Medical Services, Brooke Army Medical Center
Barry J Sheridan, DO is a member of the following medical societies: American Academy of Emergency Medicine
Disclosure: Nothing to disclose.

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Jonathan Adler, MD, Attending Physician, Department of Emergency Medicine, Massachusetts General Hospital; Division of Emergency Medicine, Harvard Medical School
Jonathan Adler, MD is a member of the following medical societies: American Academy of Emergency Medicine and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.